Latest Breaking News On - சீட்டில் புற்றுநோய் பராமரிப்பு - Page 2 : comparemela.com

Will quadruplet therapy become the standard induction therapy for newly diagnosed multiple myeloma? Currently, standard induction therapy in the U.S. for the disease is a triple therapy of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd), followed by stem cell transplantation in eligible patients and maintenance therapy with either lenalidomide or bortezomib. Investigators are now evaluating how the addition of daratumumab (Darzalex), a monoclonal antibody targeting CD38, to triplet therapy can improve outcomes for patients with newly diagnosed myeloma. We want regimens that produce the longest disease-free or progression-free survival, because they predict the best outcomes, including long-term survival, said Rafael Fonseca, MD, chair of the Department of Internal Medicine at the Mayo Clinic in Phoenix. And you do that by achieving the deepest response possible, so getting the deepest response is the most important thing for a frontline regimen at the mom

United statesRafael fonsecaAndrewj cowanMike bassettDepartment of internal medicineSeattle cancer care allianceUniversity of washington school medicineInternal medicineMayo clinicWashington schoolSeattle cancer careMultiple myelomaஒன்றுபட்டது மாநிலங்களில்ரஃபேல் ஃபாந்ஸெகமைக் பாசெட்துறை ஆஃப் உள் மருந்து